Thirty-two of 99 (32.32%) patients experienced Grade 3 and above TRAEs, including fatigue (n=15; 15.15%), neutropenia (n=13; 13.13%), thrombocytopenia (n=5; 5.05%), anemia (n=4; 4.04%), pneumonitis (n=3; 3.03%), vomiting (n=2; 2.02%), rash (n=2; 2.02%), increased alanine aminotransferase (n=1; 1.01%), and hypophysitis (n=1; 1.01%). This evidence concerns the gene GPT and Thrombocytopenia.